Recipharm hits debt and equity in Consort buy
Sweden’s Recipharm has agreed a debt-backed deal to buy the UK’s Consort Medical for an enterprise value of about £627m ($810m), as the pharmaceuticals sector remains a consistent area of M&A activity.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts